Biliary Tract Cancer
CMPXCompass TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for Tovecimig (CTX-009) (DLL4 and VEGF-A bispecific antibody) in Biliary Tract Cancer. The expected timing is based on the latest available company guidance and may change.
COMPANION-002 trial. 4/25/24- Granted Fast Track Designation. 8/6/24- Completes enrollment. 2/27/25- Report topline data by the end of Q1 2025. 4/1/25- Met primary endpoint in Ph2/3. 8/11/25- Secondary endpoints including OS data expected in Q1 2026. 11/05/25:- OS/PFS secondary endpoint data expected late Q1 2026; potential first BLA filing planned H2 2026. 03/05/26:- PFS/OS secondary endpoint analyses from COMPANION-002 expected in April 2026. 04/27/26:- COMPANION-002 met key PFS endpoint; complete dataset with DoR to present later 2026; FDA meeting planned. 05/05/26:- Ph2/3 BTC trial showed strong PFS/ORR; Orphan Drug Designation granted; first BLA submission planned H2 2026. 07/17/26:- Oral ESMO 2026 presentation of COMPANION-002 Ph2/3 BTC results on October 24, 2026. 08/06/26:- Final ORR 18%; FDA feedback Q3 2026; ESMO oral data October; BLA planned 2026.
Verification
Confirm timing and program details against the company announcement or filing.